AI Article Synopsis

  • Researchers studied the combined effects of IP10 and IL-8 in blood to identify biomarkers that predict responses to immunotherapy and chemotherapy in lung cancer and other cancers.
  • The study used a high-throughput cytokine detection platform and analyzed samples from 67 lung cancer patients and 24 with multiple cancers, determining that the ratio of IP-10 to IL-8 improved prediction accuracy for treatment responses.
  • The findings suggest that this biomarker could be effective across different types of non-small cell lung cancer (NSCLC) and various PD-1 inhibitor therapies, with further validation needed on larger patient groups for future clinical use.

Article Abstract

Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. However, there are only a few studies on biomarkers for these targeted immunotherapies, especially in peripheral blood. We first studied the role of interferon-induced protein-10 (IP10) combined with interleukin-8 (IL-8) in peripheral blood as a biomarker of immune-combined chemotherapy for lung cancer and multiple cancers. We used the high-throughput cytokine detection platform and performed bioinformatics analysis of blood samples from 67 patients with lung cancer and 24 with multiple cancers. We selected the ratio of IP-10 to IL-8 (S2/S0, ratio of changes at 10-12 weeks after treatment to baseline) to predict the response to immunotherapy combined with chemotherapy and evaluate the survival of lung cancer patients and mixed cancer patients. In patients treated with the combination therapy, the specificity and sensitivity of IL-8 and IP10 together as predictors were improved compared with those of IL-8 and IP10 alone. Our conclusion was verified in not only lung cancer but also multiple cancer research cohorts. We then further validated the predictive effect of biomarkers in different histologic types of NSCLC and chemotherapy combined with different PD-1 drug groups. Subsequent validation should be conducted with a larger number of patients. The proposed marker IP10 (S2/S0)/IL-8 (S2/S0), as a predictive immunotherapy biomarker, has broad prospects for future clinical applications in treating patients with multiple intractable neoplasms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072287PMC
http://dx.doi.org/10.3389/fimmu.2021.665147DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
multiple cancers
12
cancer multiple
12
patients lung
8
immunotherapy combined
8
combined chemotherapy
8
peripheral blood
8
cancer patients
8
il-8 ip10
8
patients
7

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!